Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Subclinical liver disease, marked by steatosis, fibrosis, and functional impairment, independently and synergistically increases cardiovascular disease risk. Incorporating non-invasive liver biomarkers could enhance CVD risk prediction and
Emerging evidence identifies KIF13B facilitating KPNA2-mediated nuclear import of PPARα as a critical mechanism to mitigate alcohol-associated liver steatosis, highlighting novel therapeutic strategies for ALD.
A 16-week RCT demonstrates that time-restricted eating significantly reduces hepatic steatosis in MASLD, offering comparable metabolic benefits to calorie restriction without adverse events.
Lanifibranor, a pan-PPAR agonist, significantly reduces liver fat and improves insulin sensitivity at multiple tissue sites in type 2 diabetes patients with MASLD, offering a new therapeutic avenue to address underlying metabolic dysfunctio
This clinical trial evaluates chitosan supplementation’s impact on liver health and metabolic markers in adults with NAFLD, showing potential benefits alongside a low-calorie diet.
A double-blind RCT found that three consecutive fecal microbiota transplantations did not significantly improve hepatic steatosis or metabolic parameters in patients with MASLD, suggesting patient selection based on microbiota diversity may